301. Macular dystrophy
41 clinical trials,   47 drugs   (DrugBank: 12 drugs),   12 drug target genes,   66 drug target pathways
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00346853 (ClinicalTrials.gov) | November 2005 | 28/6/2006 | Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy | Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation | Macular Dystrophy, Corneal | Drug: 4-Methylpyrazole;Other: saline | University of Utah | NULL | Completed | 18 Years | 65 Years | All | 10 | Phase 1 | United States |